Skip to main content
Erschienen in: BMC Urology 1/2021

Open Access 01.12.2021 | Case report

Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature

verfasst von: Pablo A. Rojas, Cristián González, Gonzalo P. Mendez, Alejandro Majerson, Ignacio F. San Francisco

Erschienen in: BMC Urology | Ausgabe 1/2021

Abstract

Background

Bladder tumors in pregnancy are extremely rare. No more than 50 cases have been published to date, including all histologic variants, and only three cases of bladder squamous cell carcinoma have been described.

Case presentation

We present a clinical case of a 31-year-old woman with bladder squamous cell carcinoma in the second trimester of pregnancy. After a C-section at 30 weeks, we performed radical cystectomy with extended bilateral lymphadenectomy, hysterectomy and right oophorectomy. The Studer neobladder technique was performed for urinary tract reconstruction. Definitive pathology showed invasive bladder squamous cell carcinoma, Grade 2, with microscopic infiltration of the perivesical fat, negative margins, and 3/28 lymph nodes with carcinoma (pT3aN2M0). The patient underwent 18 months of surveillance after radical cystectomy, without recurrence by PET-CT.

Conclusions

Bladder cancer in pregnant women is extremely rare but must be considered in those with recurrent gross hematuria and/or recurrent urinary tract infection. To our knowledge, this case involves the longest recurrence-free survival of a pregnant woman with squamous cell bladder cancer published thus far.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
MRI
Magnetic resonance imaging
TUTR
Transurethral resection
CT
Computed tomography
PNLMP
Papillary neoplasms of low malignant potential

Background

Bladder tumors inpregnancy are an extremely rare diagnosis. Currently, no more than 50 cases have been published, including all histologic variants [1].

Case presentation

We present the case of a healthy 31-year-old woman with an obstetric history of 1 pregnancy, 1 live birth, no abortions (G1P1A0), and a urinary tract infection in the first and second trimesters, without complications. At 21 weeks of gestation, the patient had gross hematuria. We performed cystoscopy and observed a lesion of 3–4 cm in the right wall not identifying the right ureteral orifice (Fig. 1). Pelvic magnetic resonance imaging (MRI) without contrast was performed and showed a bladder tumor along the right wall that was 6.3 × 3.5 × 6 cm lateral to the right ureter and lymph nodes, 13 × 9 mm in the right external iliac vessels and 10 × 7 mm in the right internal iliac vessels (Fig. 2). The patient had no predisposing factors for bladder cancer.
From an obstetric perspective, the pregnancy was normal without complications.
At 26 weeks of gestation, we performed transurethral resection (TUR) of the bladder lesion. The biopsy showed well-differentiated, invasive bladder squamous cell carcinoma (pT2). Abdominal MRI and chest computed tomography (CT) did not reveal metastatic disease. A staging study was performed after TUR to evaluate possible tumor dissemination and the need for systemic therapy.
The case was presented to a uro-oncology committee meeting and a maternal fetal medicine unit: the patient was offered the alternative of immediately terminating the pregnancy or waiting until 30 weeks for delivery and subsequently performing the surgery. The patient opted for the latter.
The patient underwent C-section at 30 weeks. The newborn was healthy, with no complications.
As recommended by the multidisciplinary committee, the patient did not receive neoadjuvant chemotherapy based on the histology of pure squamous cell carcinoma. One month after delivery, we performed open radical cystectomy with extended bilateral lymphadenectomy through the common iliac vessels and presacrum, a hysterectomy and a right oophorectomy. Blood loss was 1100 cc. There were no other complications from the surgery. The Studer neobladder technique with 60 cm of terminal ileum was performed for urinary tract reconstruction. Cystostomy was carried out, and a urethral catheter was placed for anastomosis.
The patient recovered satisfactorily and was discharged 5 days postoperatively. The ureteral stents and cystostomy were removed two weeks after surgery.
Definitive pathology revealed invasive bladder squamous cell carcinoma, Grade 2, with microscopic infiltration of the perivesical fat, negative margins, and 3/28 lymph nodes with carcinoma (pT3aN2M0, Fig. 3). Again, evaluation by a multidisciplinary committee decided not to apply adjuvant chemotherapy/immunotherapy or radiation based on the histology and the lack of residual macroscopic disease.
Twenty days after the surgery, the patient presented with abdominal pain and fever. CT with contrast revealed uroperitoneum with neobladder filtration. The patient underwent exploratory laparotomy, which revealed 1200 cc of uroperitoneum, leakage through the cystostomy site, suture line of the ileum and ureterovesical anastomosis. The filtration sites were closed with PDS sutures, and a urethral catheter and drainage were again installed. Five days after the surgery, the patient developed abdominal pain, and an increase in drainage output was observed. Cystography showed new filtration in the anterior wall of the neobladder. The patient again underwent exploratory laparotomy, revealing leakage in two points of the suture line. The filtration sites were closed with PDS sutures. No drainage output or abdominal pain occurred but spontaneous diuresis was present. The patient was discharged at 3 weeks after the first reintervention.
At present, the patient has undergone 18 months of surveillance after radical cystectomy, without recurrence by follow-up PET-CT (Fig. 4), with complete continence, day and night, and no metabolic complications. Her baby is currently 19 months old and perfectly healthy.

Discussion and conclusions

Urological tumors in pregnant women are exceedingly rare, with an estimated incidence of 0.0013%. The most frequent tumors are kidney tumors, followed by bladder tumors and finally pheochromocytomas [2].
Bladder tumors during pregnancy have been described since 1927, with transitional cell carcinoma being the most common (70%) [37]. To our knowledge, only three cases of squamous cell bladder tumors have been reported in pregnant women (Table 1). Risk factors for squamous cell bladder tumors are a history of catheter use (clean intermittent self-catheterization or an indwelling catheter), smoking and recurrent urinary tract infections [8].
Table 1
Bladder tumor in pregnant women. Prior studies
Author
Publication’s year
Number of patients
Histology
Church [1]
2013
1 patient, 27 years old
Squamous cell carcinoma
Tyagi [3]
2019
1 patient, 30 years old
Transitional cell carcinoma
Mitra [4]
2003
1 patient, 37 years old
Transitional cell carcinoma
Spahn [6]
2005
3 patients
2 transitional cell carcinoma, 1 squamous cell carcinoma
Alleemudder [7]
2016
1 patient, 39 years old
Squamous cell carcinoma
Shrotri [11]
2008
1 patient, 36 years old
Transitional cell carcinoma
Among reported cases of squamous cell tumors, the women were in the third decade of life with pregnancies in the second trimester, similar to our patient. However, due to the aggressiveness of the disease, patients died within the first year of follow-up after cystectomy [7]. Therefore, to our knowledge, the patient we present in this report has the longest recurrence-free survival described in the literature.
Gross hematuria is frequent in pregnant women (up to 80% can present it), and the most common cause is cystitis [3, 5]; considering the severity of the cases described above, cystoscopy is recommended for pregnant women with recurrent hematuria [7]. MRI can be used as a support tool for diagnosis and staging, and gadolinium can be used from the 23rd week of gestation [2]. An abdomen and pelvis CT scan is not recommended in pregnant women because the fetus will be exposed to radiation above 50 mGy, though a chest CT scan is an alternative to staging because the radiation exposure of the fetus is minimal [9].
Once the diagnosis of the bladder tumor is established, it is essential to perform TUR, which is considered a low-risk procedure at any stage of pregnancy and only carries the usual risks associated with anesthesia [3]. Bipolar TUR may be safer [7]. Using histology, it is possible to categorize patients into risk groups to define management. Low-risk patients should be monitored with cystoscopy. In high-risk patients, a restaging TUR should be performed, and management should be decided according to the histology [2]. The safety of BCG instillations is currently unclear; however, there are reports of their use during the second trimester in a patient with carcinoma in situ [2]. Mitomycin is contraindicated as intravesical therapy during pregnancy due to its teratogenic effects [4].
When establishing that the tumor is infiltrating (pT2), the case must be staged. In addition, the gestation trimester must be considered. In the first and second trimesters, the pregnancy should be terminated, followed by cystectomy [4]; in the third trimester, the recommendation is to wait until 28–30 weeks of gestation and then perform cystectomy (after 3–4 weeks). These recommendations are based on the predicted percentage survival of the fetus, which is only 3% at 22 weeks of gestation but increases to 84% at 28 weeks [4].
Performing both surgeries at once is not recommended, as it would increase the risk of bleeding, considering pelvic congestion and the difficulty of performing a hysterectomy of a pregnant uterus [2]. Regarding urinary diversion, continent and noncontinent diversions have been described, without specific recommendations for the most appropriate surgical technique.
Currently, there is no evidence regarding adjuvant therapy with chemotherapy or systemic immunotherapy in pure squamous cell bladder tumors. Postoperative radiation therapy is an alternative to local control or in cases of positive margins [10].
In conclusion, bladder cancer in pregnant women is extremely rare and must be considered in women with recurrent gross hematuria and/or recurrent urinary tract infection. The management of these cases should be performed by a multidisciplinary team. The best time to perform radical cystectomy seems to be at least 4 weeks after C-section and not at the same time. To our knowledge, this case constitutes the longest recurrence-free survival of a pregnant woman with squamous cell bladder cancer published in the literature.
This study was approved by the ethical committee of Hospital Clínico de la Pontificia Universidad Católica de Chile.
Written informed consent was obtained from the case patient for publication of this report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

Competing interests

The authors declare that they have no competing interests.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Church E, Dieh A. A rare case of aggressive squamous cell carcinoma of the bladder in pregnancy. Obstet Med. 2013;6:182–3.CrossRef Church E, Dieh A. A rare case of aggressive squamous cell carcinoma of the bladder in pregnancy. Obstet Med. 2013;6:182–3.CrossRef
2.
Zurück zum Zitat Khochikar MV. Management of urological cancers during pregnancy. Nat Rev Urol. 2010;7:195–205.CrossRef Khochikar MV. Management of urological cancers during pregnancy. Nat Rev Urol. 2010;7:195–205.CrossRef
3.
Zurück zum Zitat Tyagi S, Nelivigi G, Bhagat S. Management of bladder cancer in the second trimester of pregnancy. J Obstet Gynaecol India. 2019;69:20–3.CrossRef Tyagi S, Nelivigi G, Bhagat S. Management of bladder cancer in the second trimester of pregnancy. J Obstet Gynaecol India. 2019;69:20–3.CrossRef
4.
Zurück zum Zitat Mitra S, Williamson JG, Bullock KN, Arends M. Bladder cancer in pregnancy. J Obstet Gynaecol. 2003;23:440–2.CrossRef Mitra S, Williamson JG, Bullock KN, Arends M. Bladder cancer in pregnancy. J Obstet Gynaecol. 2003;23:440–2.CrossRef
5.
Zurück zum Zitat Muezzinoglu T, Inceboz U, Baytur Y, Nese N. Bladder carcinoma in pregnancy: unusual cause for frequent urinary tract infection-case report. Arch Gynecol Obstet. 2013;287:833–4.CrossRef Muezzinoglu T, Inceboz U, Baytur Y, Nese N. Bladder carcinoma in pregnancy: unusual cause for frequent urinary tract infection-case report. Arch Gynecol Obstet. 2013;287:833–4.CrossRef
6.
Zurück zum Zitat Spahn M, Bader P, Westermann D, Echtle D, Frohneberg D. Bladder carcinoma during pregnancy. Urol Int. 2005;74:153–9.CrossRef Spahn M, Bader P, Westermann D, Echtle D, Frohneberg D. Bladder carcinoma during pregnancy. Urol Int. 2005;74:153–9.CrossRef
7.
Zurück zum Zitat Alleemudder DI, Alleemudder AI, Harry D, Fountain S. Bladder squamous cell carcinoma in pregnancy. J Obstet Gynaecol. 2016;36:388–9.CrossRef Alleemudder DI, Alleemudder AI, Harry D, Fountain S. Bladder squamous cell carcinoma in pregnancy. J Obstet Gynaecol. 2016;36:388–9.CrossRef
8.
Zurück zum Zitat Manley KV, Hubbard R, Swallow D, Finch W, Wood SJ, Biers SM. Risk factors for development of primary bladder squamous cell carcinoma. Ann R Coll Surg Engl. 2017;99:155–60.CrossRef Manley KV, Hubbard R, Swallow D, Finch W, Wood SJ, Biers SM. Risk factors for development of primary bladder squamous cell carcinoma. Ann R Coll Surg Engl. 2017;99:155–60.CrossRef
10.
Zurück zum Zitat Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329–54.CrossRef Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18:329–54.CrossRef
11.
Zurück zum Zitat Shrotri KN, Ross GC. Bladder carcinoma presenting during twin pregnancy. J Obstet Gynaecol. 2008;28:750–1.CrossRef Shrotri KN, Ross GC. Bladder carcinoma presenting during twin pregnancy. J Obstet Gynaecol. 2008;28:750–1.CrossRef
Metadaten
Titel
Bladder squamous cell carcinoma in a pregnant woman: case report and review of the literature
verfasst von
Pablo A. Rojas
Cristián González
Gonzalo P. Mendez
Alejandro Majerson
Ignacio F. San Francisco
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
BMC Urology / Ausgabe 1/2021
Elektronische ISSN: 1471-2490
DOI
https://doi.org/10.1186/s12894-020-00772-6

Weitere Artikel der Ausgabe 1/2021

BMC Urology 1/2021 Zur Ausgabe

Neu im Fachgebiet Urologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Prostatakarzinom: EU initiiert neues Screeningkonzept

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Blasenkarzinom – Biomarker statt Zytologie?

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.